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Abstract
Background: older people may be less likely to receive interventions than younger people. Age bias in national guidance
may inﬂuence entire public health and health care systems. We examined how English National Institute for Health & Care
Excellence (NICE) guidance and guidelines consider age.
Methods: we undertook a documentary analysis of NICE public health (n = 33) and clinical (n = 114) guidelines and tech-
nology appraisals (n = 212). We systematically searched for age-related terms, and conducted thematic analysis of the para-
graphs in which these occurred (‘age-extracts’). Quantitative analysis explored frequency of age-extracts between and within
document types. Illustrative quotes were used to elaborate and explain quantitative ﬁndings.
Results: 2,314 age-extracts were identiﬁed within three themes: age documented as an a-priori consideration at scope-setting
(518 age-extracts, 22.4%); documentation of differential effectiveness, cost-effectiveness or other outcomes by age (937 age-
extracts, 40.5%); and documentation of age-speciﬁc recommendations (859 age-extracts, 37.1%). Public health guidelines
considered age most comprehensively. There were clear examples of older-age being considered in both evidence searching
and in making recommendations, suggesting that this can be achieved within current processes.
Conclusions: we found inconsistencies in how age is considered in NICE guidance and guidelines. More effort may be
required to ensure age is consistently considered. Future NICE committees should search for and document evidence of
age-related differences in receipt of interventions. Where evidence relating to effectiveness and cost-effectiveness in older
populations is available, more explicit age-related recommendations should be made. Where there is a lack of evidence, it
should be stated what new research is needed.
Keywords: older-age, NICE guidance, clinical, public health, technology appraisal
Introduction
Substantial research has examined inequity of access to
and receipt of health care and public health interventions
by age [1–3]. Older people may be less likely to receive
potentially beneﬁcial interventions, due to factors at
individual, family, community and system level [1, 4–7],
leading to worse outcomes [8]. Given current trends
towards an ageing population [9], it is important to under-
stand where and why age-related differences in access to
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and receipt of effective interventions occur and identify
strategies to overcome these.
In the UK, the National Service Framework for Older
People (2001) highlighted the need for ‘rooting out age-
discrimination’ (p12) in Health and Social Care [10]. The
UK Equality Act (2010) came into force on 1st October
2012 making age discrimination in the provision of services
and public functions, including health care and public health,
unlawful. Where age is considered a relevant factor in clin-
ical and public health decision-making, the Equality Act
(2010) requires ‘objective justiﬁcation’ (p10) in accordance
with evidence-based guidelines [11]. Elsewhere, the World
Health Organization is consulting on a Global Strategy and
Action Plan on Ageing and Health with a focus on equitable
access to interventions [12].
One important source of information for those planning
and delivering public health and health care interventions is
national guidance and guidelines. In England, the National
Institute for Health & Care Excellence (NICE) produces
evidence-based guidance (mandatory) and guidelines (advis-
ory) for health, public health and social care (see Box 1).
NICE is internationally recognised as a role model in this
area [13]. If age, or other, biases are present in guidance
and guidelines, this may inﬂuence entire systems.
We sought to understand whether and how age is con-
sidered in NICE guidelines and guidance.
Methods
We systematically searched three types of NICE documents to
identify all references to age and categorised these into themes.
We then explored the frequency of these references to age
overall and within themes, within and across document types.
Document inclusion criteria
We included three types of documents of most relevance to
health and care practitioners: clinical guidelines, public
health guidelines and technology appraisals (see Box 1).
NICE guidance and guidelines are produced in multiple
formats and each ﬁnal guideline or guidance is accompan-
ied by a variety of supporting documents. We focused on
ﬁnal documents that professionals searching for these
would be likely to ﬁnd and use.
Documents available from the list at http://www.nice.
org.uk/guidance in July 2014 were considered for inclusion.
This list included full versions of public health guidelines
and technology appraisals, and shortened versions of clin-
ical guidelines. We did not include supporting documents or
‘fuller’ versions of clinical guidelines. Guidelines and guid-
ance speciﬁc to young people, children, or pregnant women
were excluded. Documents for exclusion were identiﬁed by
L.F.F. and independently checked by N.P. Disagreements
were resolved by discussion.
Document searching and data extraction
A systematic electronic search of included documents was
used to locate all references to ‘age’, ‘old’, ‘elder’ and related
terms, e.g. ‘aged’, ‘older’ and ‘elderly’. When such age-
related terms were identiﬁed, the full paragraph around
each (referred to as ‘age-extracts’) was extracted verbatim
for thematic analysis. This ensured that context and mean-
ing were retained during analysis, but meant that more than
one age-related term could be included per age-extract.
Age-extracts were the primary unit of analysis.
Analysis and presentation of data
Age-extracts were coded using a framework of themes and
subthemes, which was inductively and iteratively developed
by L.F.F. and checked by S.B. We identiﬁed the total num-
ber of age-extracts falling within each theme and subtheme,
as well as the number speciﬁcally referring to older-age. A
number of themes were excluded from further consider-
ation. These were use of ‘age’ unrelated to chronological
human age (e.g. the age of studies); age included in job titles
Box 1. National Institute for Health & Clinical Excellence (NICE) guidance and guidelines
NICE guidelines make recommendations that are determined by independent committees on a wide range of topics, based on the best available evidence of
what works, and what it costs. NICE also produces social value judgements relating to equity that committees must take into account when making
recommendations. Guidance are developed using similar processes, but are mandatory. We included two types of guidelines and one type of guidance in this
study:
Public health guidelines
These are advisory and make recommendations for populations and individuals in relation to activities, policies and strategies that can help prevent disease or
improve health.
NICE clinical guidelines
These are recommendations on how health care professionals and others should care for people with speciﬁc conditions. Healthcare professionals are advised
to take the guidelines into account when exercising clinical judgement, while making decisions appropriate to the individual circumstances and wishes of
patients.
Technology appraisals
These provide statutory guidance on clinical needs and practice when prescribing drugs or technologies to improve health outcomes or prevent disease, and
thus are mandatory.
L. F. Forrest et al.
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(e.g. Professor of Old Age Psychiatry); references to other
NICE guidance; and references to children only.
Data extraction and thematic coding were conducted by
L.F.F. Five random age-extracts per theme were checked by
S.B. Disagreements were resolved by discussion.
We tabulated the total number of age-extracts overall,
and within each theme and subtheme, across document
types. We used Poisson regression (after checking that
assumptions were met) to compare the total number of
age-extracts across document type, using the log number of
documents as the offset. We derived the relative rate of
age-extracts by exponentiating the coefﬁcients and tested
for heterogeneity by using the Wald test for document type.
The results section presents quantitative information
with example quotes from age-extracts used to illustrate
and help explain this.
Results
A total of 359 documents containing 2,314 age-extracts
(a mean of 6.4 age-extracts per document) were included in the
analyses. Age-extracts fell into three themes: age documented
as an a-priori consideration at scope-setting; documentation of
differential effectiveness, cost-effectiveness or other outcomes
by age; and documentation of age-speciﬁc recommendations.
Table 1 shows the distribution of age-extracts overall
and within themes, across document types. Public health
(relative rate 2.68, 95% CI 2.41 to 2.99, P < 0.001) and
clinical guidelines (relative rate 1.14, 95% CI 1.04 to 1.25,
P = 0.006) contained a greater number of age-extracts than
technology appraisals (comparator), with strong evidence of
statistical heterogeneity (P < 0.001).
Table 2 details the framework of included themes and
subthemes, with the number of age-extracts in these by
document type. Below, we discuss key ﬁndings within each
theme.
Theme 1: age documented as an a-priori consideration
in guidance scope
Almost half of clinical guidelines (n = 49, 43%) and a quar-
ter of public health guidelines (n = 8, 24%) and technology
appraisals (n = 81, 23%) were aimed at age-speciﬁc groups.
Very few of any type of document were aimed at older-age
groups speciﬁcally (n = 15, 4%).
Only public health guidelines documented considering
age at scope-setting, although this was done in less than
half of cases (n = 14, 42%). On 11 occasions, the same
question was listed: ‘Does the effectiveness of the interven-
tion vary with different characteristics within the target
population, such as age?’. This question was not documen-
ted in any technology appraisals or clinical guidelines.
Public health guidelines (n = 25, 76%) were more likely
than clinical guidelines (n = 22, 19%) or technology apprai-
sals (n = 44, 21%) to report statistics describing the prob-
lem addressed by age. Similarly, public health guidelines
were more likely to describe why age might be an important
factor to consider than other documents. However, this
was only done in one-third (n = 11, 33%) of public health
guidelines. Around one-third of all documents identiﬁed
age as a risk factor for the problem addressed (n = 105,
29%), particularly older-age (n = 87, 24%).
Box 2 provides illustrative quotations from age-extracts
coded within theme 1.
Theme 2: documentation of differential effectiveness,
cost-effectiveness or other outcomes by age
Detailed considerations of evidence of effectiveness and cost-
effectiveness were not included in the clinical guideline docu-
ments included. While no clinical guidelines described age-
related evidence limitations on cost-effectiveness, 17 (15%)
described age-related limitations in evidence of effectiveness.
These primarily related speciﬁcally to older-age (n = 12, 11%).
Overall, public health guidelines were at least twice as
likely as technology appraisals to report evidence of differ-
ential effectiveness and cost-effectiveness by age, as well as
age-related evidence gaps in evidence of effectiveness and
cost-effectiveness. While the majority of evidence statements
of differential effectiveness by age speciﬁcally related to
older-age, this was not the case for cost-effectiveness evi-
dence statements and age-related evidence gaps.
A number of evidence statements in public health guide-
lines were based on qualitative work relating to understanding
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Distribution of age-extracts overall and within themes across document type
Public health guidelines (n = 33) Clinical guidelines (n = 114) Technology appraisals (n = 212) Total (n = 359)
All themes
Age-extracts, n 476 699 1,139 2,314
Mean age-extracts/document, n 14.4 6.1 5.4 6.4
Theme 1: Age documented as an a-priori consideration in guidance scope
Age-extracts, n 127 213 178 518
Mean age-extracts/document, n 3.8 1.9 0.8 1.4
Theme 2: Documentation of differential effectiveness, cost-effectiveness or other outcomes by age
Age-extracts, n 193 47 697 937
Mean age-extracts/document, n 5.8 0.4 3.3 2.6
Theme 3: Documentation of age-speciﬁc recommendations
Age-extracts, n 156 439 264 859
Mean age-extracts/document, n 4.7 3.9 1.2 2.4
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Table 2. Age-related themes and subthemes in public health, clinical and technology appraisal guidance
Theme and subtheme Public health (n = 33) Clinical (n = 114) Technology appraisal (n = 212) Total (n = 359)
Documents,
n (%)
Age-extracts,
n
Documents,
n (%)
Age-extracts,
n
Documents,
n (%)
Age-extracts,
n
Documents,
n (%)
Age-extracts,
n
Theme 1: Age documented as an a-priori consideration in guidance scope
Age of population guidelines aimed at 8 (24) 11 49 (43) 98 24 (11) 34 81 (23) 143
Age of population guidelines aimed at (older-age speciﬁc) 1 (3) 3 6 (5) 42 8 (4) 9 15 (4) 54
Age in guideline scope 14 (42) 17 0 0 0 0 14 (4) 17
Age in guideline scope (older-age speciﬁc) 2 (6) 3 0 0 0 0 2 (1) 3
Statistics describing problem by age 24 (73) 61 22 (19) 31 44 (21) 54 90 (26) 146
Statistics describing problem by age (older-age speciﬁc) 6 (18) 10 14 (12) 15 25 (12) 27 45 (13) 52
Age stated as risk factor for problem 10 (30) 18 39 (34) 64 56 (26) 81 105 (29) 163
Age stated as risk factor for problem (older-age speciﬁc) 8 (24) 11 29 (25) 36 50 (24) 64 87 (24) 111
Statement of why age is an important factor to consider 11 (33) 20 18 (16) 20 8 (4) 9 37 (10) 49
Statement of why age is an important factor to consider (older-age speciﬁc) 6 (18) 9 8 (7) 9 6 (3) 7 20 (6) 25
Theme 2: Documentation of differential effectiveness, cost-effectiveness or other outcomes by age
Age as an inclusion criterion in effectiveness studies 13 (39) 42 0 0 74 (35) 151 87 (24) 193
Evidence statements of differential effectiveness by age 16 (49) 66 4 (4) 12 33 (16) 61 53 (15) 139
Evidence statements of differential effectiveness by age (older-age speciﬁc) 15 (46) 47 4 (4) 12 14 (7) 27 33 (9) 86
Limitations or gaps in evidence of effectiveness by age 13 (39) 24 17 (15) 21 24 (11) 35 54 (15) 80
Limitations or gaps in evidence of effectiveness by age (older-age speciﬁc) 4 (12) 12 12 (11) 15 9 (4) 14 25 (7) 41
Age used in cost-effectiveness models 0 0 0 0 80 (38) 167 80 (22) 167
Evidence statements of differential cost-effectiveness by age 15 (46) 32 2 (2) 2 44 (21) 144 61 (17) 178
Evidence statements of differential cost-effectiveness by age (older-age
speciﬁc)
6 (18) 11 2 (2) 2 24 (11) 83 32 (9) 96
Limitations or gaps in evidence of cost-effectiveness by age 7 (21) 9 0 0 26 (12) 40 33 (9) 49
Limitations or gaps in evidence of cost-effectiveness by age (older-age
speciﬁc)
2 (6) 3 0 0 6 (3) 8 8 (2) 11
Age as a reason why interventions not offered/ineffective in older people 7 (21) 19 5 (4) 5 21 (10) 34 33 (9) 58
Age of those included in trials different to those at risk 1 (3) 1 0 0 33 (16) 49 34 (10) 50
Adverse effects in older people 0 0 6 (5) 7 13 (6) 16 19 (5) 23
Theme 3: Documentation of age-speciﬁc recommendations
Age taken into consideration when making recommendations 22 (67) 39 0 0 82 (39) 220 104 (29) 259
Equality Act taken into consideration when making recommendations 1 (3) 1 0 0 10 (5) 16 11 (3) 17
Target population for recommendations age speciﬁc 7 (21) 15 0 0 0 0 7 (2) 15
Target population for recommendations (older-age speciﬁc) 3 (9) 9 0 0 0 0 3 (1) 9
Priority for implementation of recommendations age speciﬁc 0 0 31 (27) 47 0 0 31 (9) 47
Priority for implementation of recommendations (older-age speciﬁc) 0 0 17 (15) 22 0 0 17 (5) 22
Further effectiveness research recommended by age 22 (67) 34 31 (27) 60 4 (2) 4 57 (16) 98
Further effectiveness research recommended by age (older-age speciﬁc) 4 (12) 11 19 (17) 45 2 (1) 2 25 (7) 58
Further cost-effectiveness research recommended by age 13 (39) 21 6 (5) 7 0 0 19 (5) 28
Further cost-effectiveness research recommended by age (older-age speciﬁc) 4 (12) 10 3 (3) 4 0 0 7 (2) 14
Other age-related recommendations 18 (55) 47 73 (64) 325 14 (7) 40 105 (29) 412
Other age-related recommendations (older-age speciﬁc) 8 (24) 17 48 (42) 149 8 (4) 28 64 (18) 194
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of risk, and of the relevance, appropriateness or acceptability
of an intervention for older populations. Some public health
guidelines also referred to factors that might account for low-
er uptake or effectiveness of interventions in older popula-
tions, such as frailty, poorer health, age-related differences in
perception of relative risk, use of tools designed for younger
people and scarcity of resources.
A number of technology appraisals (n = 33, 16%) and
public health guidelines (n = 1, 3%) noted that the age pro-
ﬁle of those included in relevant trials was generally younger
to the age proﬁle of those at risk of the problem studied.
Illustrative quotes from age-extracts in theme 2 are
shown in Box 3.
Theme 3: documentation of age-speciﬁc
recommendations
Two-thirds of public health guidelines (n = 22, 67%), no
clinical guidelines and two-ﬁfths of technology appraisals
(n = 82, 39%) documented that they took age into account
when making recommendations. Many of these recommen-
dations focused on ensuring people were not excluded
from interventions on the basis of age alone.
Throughout, there were many documented discussions
of whether age should be taken into account in recom-
mendations and, in documents published since 2012,
whether recommendations should be revised in light of
the Equalities Act (2010). No such revisions were recom-
mended and documents often concluded that intervention
decisions should be made on an individual basis.
Evidence of effectiveness and cost-effectiveness of
new technologies are often supplied by manufacturers to
NICE technology appraisal panels. Panels appear to spend
substantial time testing and discussing this evidence. Age is
regularly examined during this process (n = 82, 39%), but
mostly in terms of how it is used in cost-effectiveness models.
Only public health guidelines made age-speciﬁc practice
recommendations, but only in one-ﬁfth of cases (n = 7,
21%). Less than half of these recommendations were spe-
ciﬁc to older-age (n = 3, 9%). In contrast, only clinical
guidelines prioritised practice recommendations according
to age, but these were only present in one-quarter (n = 31,
27%). Around half were older-age speciﬁc (n = 17, 15%).
Age-speciﬁc research recommendations were present
across guideline types—but were least often found in tech-
nology appraisals. Two-thirds (n = 22, 67%) of public
health guidelines included recommendations for further
age-speciﬁc effectiveness evidence and more than one-third
(n = 13, 39%) for further age-speciﬁc cost-effectiveness evi-
dence. Comparable ﬁgures for clinical guidelines were 31
(27%) and 6 (5%); and for technology appraisals were 4
(2%) and 0. In most cases, less than half of these were
older-age speciﬁc.
Box 4 shows illustrative quotations from age-extracts in
theme 3.
Discussion
Summary of ﬁndings
This is the ﬁrst attempt we are aware of to analyse how age
in general, and older-age in particular, is considered in
national health and health care guidelines and guidance.
Using NICE as a case study, we found 2,314 age-extracts
across 359 public health and clinical guidelines and technol-
ogy appraisals. These fell into three broad themes: age
documented as an a-priori consideration at scope-setting;
documentation of differential effectiveness, cost-effectiveness
or other outcomes by age; and documentation of age-speciﬁc
recommendations.
Age was not considered consistently across the three
document types. In general, public health guidelines con-
sidered age more comprehensively, but this was still not
consistent across all public health guidelines.
A lack of explicit age-related recommendations within
guidelines and guidance could result in uncertainties for
Box 2. Illustrative quotations from age-extracts within theme 1
Age in guideline scope
‘Are interventions tailored to sub-sets of the smoking population (for example, pregnant women, older smokers) more effective with them than generic
interventions?’ PH1 Brief interventions and referral for smoking cessation
‘How does the effectiveness vary with age, gender, class, ethnicity, etc.?’ PH2 Four commonly used methods to increase physical activity
‘What are the most effective and cost-effective ways for primary and residential care services to promote the mental wellbeing of older people?’ PH16
Occupational therapy and physical activity interventions to promote the mental wellbeing of older people in primary care and residential care
Statistics describing problem considered by age
‘53% of men aged 16–24 achieved the recommended activity levels, compared with 8% of men aged 75 and over. Among women, 29–31% aged 16–54
reached the recommended level. However, the same was only true of 3% of women aged 75 and over.’ PH2 Four commonly used methods to increase physical
activity
Age stated as risk factor for problem considered
‘In people between the ages of 45 and 49 years, the incidence is about 20 per 100,000. In those aged 75 and older, the annual incidence is over 300 cases per
100,000 men and over 200 cases per 100,000 women.’ TA105 Laparoscopic surgery for colorectal cancer
Statements of why age is an important factor to consider
‘More than 250,000 older people (aged 66 and older) living in England in private households reported experiencing maltreatment from a family member.’
PH50 Domestic violence and abuse – how services can respond effectively
Age-related references in national public health, technology appraisal and clinical guidelines
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practitioners and commissioners. In the absence of evi-
dence, guideline developers might choose to highlight the
need for further research. While many public health guide-
lines did this, few technology appraisals and clinical guide-
lines did so.
Study limitations
NICE produces a range of different guidelines and guidance.
We focused on clinical and public health guidelines and tech-
nology appraisals as we considered these to be most relevant
for practitioners and commissioners. Although multiple docu-
ments related to each guideline and piece of guidance are
available, we focused on the most front-facing of these that
practitioners would be most likely to ﬁnd. This maximised
the relevance of our ﬁndings. However, our ﬁndings are not
necessarily generalisable to other types of NICE document,
or to other countries.
Documentary analysis is labour intensive and time-
consuming [14]. We searched and extracted data from hun-
dreds of large documents. It was not feasible to read all of
these in full. Instead we automated searching for extracts,
but coded these by hand. Duplicate thematic coding helped
increase the validity of this.
It would have been interesting to formally test our quali-
tative assessment that the Equalities Act inﬂuenced how
age was considered. However, small numbers in many cells
in Table 2 meant this was not considered appropriate.
Box 3. Illustrative quotations from age-extracts within theme 2
Evidence statements of differential effectiveness/cost-effectiveness by age
‘One…study reports a reduction in effectiveness in promoting CVD [cardio-vascular disease] awareness in older participants. Two…studies report no
differences in effectiveness according to age.’ PH25 Prevention of cardiovascular disease
‘A meta-analysis of exercise capacity with dual-chamber pacing compared with single-chamber ventricular pacing demonstrated no difference…for patients
older than 75 years…but there was…for patients younger than 75.’ TA88 Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and or
atrioventricular block
Limitations or gaps in evidence of effectiveness/cost-effectiveness by age
‘there are…no studies speciﬁcally addressing people aged 75 and over.’ CG180 The management of atrial ﬁbrillation
‘No evidence was found of effective or cost-effective interventions to promote mental wellbeing in older people living in residential care.’ PH16 Mental wellbeing
and older people
Age as a reason why interventions not offered/ineffective in older people
‘One qualitative study…found that age was widely perceived to inﬂuence access to services…Focus groups revealed that staff appeared to have knowledge of
the beneﬁts for older people but that scarcity of resources prevented them offering more accessible and appropriate services.’ PH15 Identifying and supporting
people most at risk of dying prematurely
‘The PDG [programme development group] considered that people over age 74…might beneﬁt from type 2 diabetes risk assessment and prevention…
However, it recognised that many of the risk-assessment tools are not validated for this age group.’ PH38 Preventing type 2 diabetes – risk identiﬁcation and
interventions for individuals at high risk
Age of those included in trials different to that those at risk
‘The Committee…noted that the mean age of patients in the trial was 56 years but…the average age of men with gout in UK practice was around 10 years
older.’ TA291 Gout (tophaceous, severe debilitating, chronic) – pegloticase
Box 4. Illustrative quotations from age-extracts within theme 3
Age taken into consideration when making recommendations
‘a small population of older patients who are not ﬁt enough to receive chemotherapy may not have access to an alternative treatment and so may be
disadvantaged. The Committee agreed that this was not an issue of age discrimination because other factors can also affect whether people are ﬁt enough to
receive chemotherapy, such as comorbidities.’ TA257 Breast cancer (metastatic hormone receptor) – lapatinib and trastuzumab (with aromatase inhibitor)
‘The Committee considered whether NICE’s duties under the equalities legislation required it to alter or to add to its recommendations…the Committee
concluded that…there was no need to alter or add to its recommendations.’ TA282 Idiopathic pulmonary ﬁbrosis – pirfenidone
Target population for recommendations age speciﬁc
‘All COPD patients still smoking, regardless of age, should be encouraged to stop, and offered help to do so, at every opportunity.’ CG101 Chronic obstructive
pulmonary disease
‘Offer people aged 80 years and over the same antihypertensive drug treatment as people aged 55–80 years, taking into account any comorbidities.’ CG127
Hypertension
‘Patient-speciﬁc factors (including age…) should not be barriers to referral for joint surgery.’ CG177 Osteoarthritis
Further effectiveness/cost-effectiveness research recommended by age
‘How does effectiveness and cost effectiveness vary for…people aged 75 and over?’ PH32 Type 2 diabetes
‘Future studies should be sufﬁciently powered to detect changes in mental wellbeing…In addition, the outcome measures used should be appropriate to
detect change across different groups of older people.’ PH16 Mental wellbeing and older people
L. F. Forrest et al.
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There was inconsistency in the information included in
the different types of documents studied. In particular, the
clinical guideline documents included did not incorporate
the evidence used to make recommendations (although this
is available elsewhere), while public health guidelines and
technology appraisal documents did. This may explain
some of the differences between document types found.
Reporting variations may also reﬂect variations in approach.
Using documentary analysis meant we only included
information that had been documented. Committees
developing guidance and guidelines may have considered
many issues that were not explicitly recorded in included
documents.
We searched speciﬁcally for age-related terms. Instances
when age was indirectly referred to, for example in terms of
life expectancy or frailty, may have been excluded, under-
estimating the frequency of age-extracts. However, there is
little reason to believe this would vary systematically across
document types and so constitute bias.
We excluded guidance and guidelines with a speciﬁc
focus on children, young people and pregnant women. We
did not make judgements about which included docu-
ments should have considered age. However, it could be
argued that all should have done—even if just to state that
guidance and guidelines were relevant across the age
spectrum.
It is unclear how much impact NICE guidance has on
either front-line practice or what services are prioritised for
funding at a local or national level and thus how much the
differences identiﬁed here might inﬂuence practice [15].
However, it has been suggested that increasing the speciﬁ-
city of guidelines is likely to improve implementation [16].
Interpretation of results
Since the implementation of the UK Equality Act (2010) in
2012, which made age discrimination in the provision of ser-
vices and public functions unlawful, NICE is legally obliged
to ensure that age discrimination does not occur. While the
Act does appear to have resulted in age being more explicitly
considered in technology appraisals, this often appeared to
involve a post-hoc check for compliance, rather than an inte-
gration of the Act’s principles throughout the development
process. It is possible that further developments to embed
the principles of the Equality Act (2010) in NICE processes
are planned, but we are not aware of anything in particular.
Legal obligations are only one aspect of equity. The con-
cept of ‘embedded inequity’ proposes that consideration
should also be made of whether omissions in methodo-
logical process, outcome measures, and individual context
and circumstances might lead to discrimination [17]. As
others have reported [18], we found that public health
guidelines appear to more consistently (but not universally)
include consideration of age than other included docu-
ments. This may reﬂect the use of a conceptual framework
to inform public health guidance development and explicitly
consider inequalities since at least 2009. While some NICE
processes help ensure embedded equity, others do not.
Nearly half of public health guidelines and one-ﬁfth of
technology appraisals reported evidence of differential
effectiveness and cost-effectiveness by age. Interventions
may be less cost-effective in older people due to their short-
er life expectancy [19]. However, in many instances where
prevalence increases with age, numbers needed to treat will
be smaller in older people and this may increase the cost-
effectiveness of some interventions. Furthermore, the bene-
ﬁts of interventions to older people, in terms of reduced
morbidity, improved quality of life and maintained inde-
pendence, are likely to be different, but no less valuable,
than those to younger people [20]. More consideration of
how age-related differences in beneﬁt can be taken into
account in cost-effectiveness calculations is required as well
as consideration of alternative methodological approaches
that may be more suited for older people [21].
Comparison with previous ﬁndings
Others have found, in different contexts, a lack of clear age-
related clinical recommendations [22] and suggested that
NICE make explicit reference to age where there is evidence
of age-related inequities in receipt of interventions [22].
However, little is known about whether, and where, age-
related inequities in receipt of health care and public health
interventions occur. More concerted and systematic action is
required to identify age-related differences in receipt inter-
ventions to guide development of guidelines and guidance.
Implications for research, policy and practice
A lack of evidence on effectiveness and cost-effectiveness
in older populations was often noted in included docu-
ments. Some might argue that it is unwise to provide inter-
ventions without evidence of effectiveness or cost-
effectiveness. This is likely to result in age-related differ-
ences in receipt of interventions. Others may feel that older
people should have access to all interventions until such
time as evidence emerges of a lack of effectiveness or cost-
effectiveness. While the Equality Act (2010) would favour
the latter approach, over-provision of ineffective interven-
tions to older people may result in iatrogenesis and waste.
Research on the effectiveness and cost-effectiveness of
interventions in older populations is required to overcome
any ambiguity in who should be offered interventions. Until
this is available, clear guidance on how practitioners should
act in the face of absence of evidence is required.
Many included documents identiﬁed, as previously [21,
23], that the age proﬁle of those included in trials and eva-
luations was not representative of the population most at
risk. There is little scientiﬁc justiﬁcation for this. Future
research should focus on providing evidence relevant to
populations most at risk.
In several instances, documents avoided the issue of
chronological age by referring to biological age, frailty or
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‘ﬁtness’, leaving decisions on assessment of these to practi-
tioners. Variability in how practitioners make such judgements
may be due to unconscious prejudices [24]. Better understand-
ing is required of how the risks and beneﬁts of interventions
are evaluated by practitioners and older people in the absence
of explicit guidance, and what contributions these assessments
may make to inequalities in receipt of interventions.
Conclusions
We found inconsistencies in how age is considered in
NICE public health and clinical guidelines and technology
appraisals. There were some clear examples of older-age
being considered in both searching for evidence and in
making speciﬁc recommendations, suggesting that this can
be achieved within current processes.
NICE deserves credit for openly discussing equity issues
in decision-making [25]. More effort may be required to
ensure age is consistently considered across all processes.
Future NICE guidance should systematically search for and
document evidence of age-related differences in receipt of
interventions. Where evidence is available relating to effect-
iveness and cost-effectiveness in older populations, more
explicit age-related recommendations should be made.
Where there is a lack of evidence, guidance should formally
state what new research is needed.
Key points
• Age bias in national guidance may inﬂuence entire public
health and health care systems.
• Documentation of how age and older-age were consid-
ered in English national guidance and guidelines was not
consistent.
• There were some clear examples of older-age being con-
sidered in both evidence searching and in making
recommendations.
• More effort may be required to ensure age is consistently
considered across all processes.
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